Current Report · Items 7.01, 9.01 · 8-K

Lantern Pharma Inc.

LTRNNASDAQEQUITYCurrent

Regulation FD Disclosure

Filed Sep 23, 2026Accepted Sep 23, 2026, 7:45 AM EDTCIK 1763950Accession 0001493152-26-043808

Company context

We are an artificial intelligence (A.I.) focused company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Our development portfolio includes three clinical stage oncology focused product candidates and consists of small molecules that others have tried, but failed, to develop into an approved commercialized drug, as well as new compounds that we are developing with the assistance of our proprietary A.I. platform and our biomarker driven approach. Our A.I. platform, known as RADR®, currently includes more than 200 billion data points, and uses big data analytics (combining molecular data, drug efficacy data, data from historical studies, data from scientific literature, phenotypic data from trials and publications, and mechanistic pathway data) and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds. We believe our data-driven, genomically-targeted and biomarker-driven approach allows us to pursue a transformational drug development strategy that identifies, rescues or develops, and advances potential small molecule drug candidates at what we believe is a fraction of the time and cost associated with traditional cancer drug development. On average, our newly developed drug programs have been advanced from initial A.I. insights to first-in-human clinical t

Current securities

LTRNNASDAQ · EQUITY · Current

Recent company filings

Registered securities in this filing

Lantern Pharma Inc. · 8-K · Filed 2026-09-23

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, $0.0001 par value

Symbol: LTRN
Exchange: NASDAQ
Classification: COMMON
Status: Current

Filing context

Context: AsOf2026-09-23

Dimensions: Not supplied

Accession 000149315226043808 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 7.01Item 7.01 - Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 23, 2026, Lantern Pharma Inc. (the “Company”) will issue a press release describing topics to be covered during a live webinar hosted by the Company on September 23, 2026 to discuss Open-Medicine AI, a multi-agentic AI platform for drug development. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.

Filed exhibits (1)

EX-99.1 (by filename) ex99-1.htm

Exhibit 99.1 Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET Management will also discuss usage patterns, key future milestones, and an overview of the types of collaborations and partnerships under discussion Investors, collaborators, prospective partners, and interested parties are encouraged to register and see a live demonstration of the platform’s key capabilities: Register Here DALLAS - September 23, 2026 - Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, will present the growth plan for Open-Medicine AI (OMAI) in a live webinar today at 12:30 PM Eastern. Open Medicine AI is the company’s wholly owned subsidiary building a multi-agentic AI platform for drug development. To register: https://us06web.zoom.us/webinar/register/9417895172347/WN_HNnjzsDuTjufesN-cdwaNw#/registration CEO Panna Sharma will lead the session and will be joined by the Chief Scientific Officer of Lantern Pharma and the Principal Architect of the mu…

Open exhibit ↗